Recent drug development efforts targeting Alzheimer's disease (AD) have failed to produce
effective disease-modifying agents for many reasons, including the substantial …

BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and
characterized in 1999. It is required for the generation of all monomeric forms of amyloid-β …

Blood–brain barrier (BBB) dysfunction, eg, increase in BBB permeability, has been reported
to contribute to cognitive impairment. However, the effects of anesthesia and surgery on BBB …

Aging is a dynamic and progressive process that begins at conception and continues until
death. This process leads to a decrease in homeostasis and morphological, biochemical …

Alzheimer's disease (AD) is a mostly sporadic brain disorder characterized by cognitive
decline resulting from selective neurodegeneration in the hippocampus and cerebral cortex …

The neuropathogenesis of postoperative delirium remains mostly unknown. The gut
microbiota is implicated in the pathogenesis of neurological disorders. We, therefore, set out …

Alzheimer's disease is a chronic and degenerative condition that had no treatment until
recently. The current therapeutic strategies reduce progression of the disease but are …

Background: Alzheimer's disease (AD) mortality rates have steadily increased over time.
Lithium, the current gold standard treatment for bipolar disorder, can exert neuroprotective …

Lithium has long been used for the treatment of psychiatric disorders, due to its robust
beneficial effect as a mood stabilizing drug. Lithium's effectiveness for improving …

Lithium is most well-known for its mood-stabilizing effects in the treatment of bipolar
disorder. Due to its narrow therapeutic window (0.5-1.2 mM serum concentration), there is a …